博瑞生物医药（苏州）股份有限公司“博瑞转债”赎回暨摘牌公告深度解读
一、公告核心要点
- 赎回登记日：2026年5月21日
- 赎回价格：100.9452元/张（含当期应计利息），个人投资者税后为100.7562元/张
- 赎回款发放日：2026年5月22日
- 最后交易日：2026年5月18日
- 最后转股日：2026年5月21日
- 摘牌时间：2026年5月22日，“博瑞转债”将在上交所正式摘牌
- 赎回理由：公司股票价格在规定的30个交易日内，有15个交易日收盘价达到或超过可转债转股价的130%，已触发强制赎回条款
二、详细内容与投资者须知
博瑞生物医药（苏州）股份有限公司（简称“公司”）于2026年4月27日召开董事会，依据此前可转债募集说明书约定，决定行使“博瑞转债”的提前赎回权。触发赎回的直接原因是，公司股票自2026年4月7日至2026年4月27日，连续30个交易日中有15个交易日收盘价不低于当期转股价的130%。
赎回条款与细节
- 赎回价格以每张100元面值加上自上一次付息日至赎回日应计利息（0.9452元/张）计，共100.9452元/张。
- 持有“博瑞转债”的个人投资者需缴纳利息部分20%的个人所得税，税后实际到账金额为100.7562元/张。
- 居民企业持有者自缴企业所得税，税前派发金额为100.9452元/张。
- 合格境外机构投资者（QFII、RQFII）可享受企业所得税和增值税暂免征收政策，实际派发金额为100.9452元/张。
对投资者的影响与风险提示
- 赎回价格与市场价差异巨大：截至2026年5月13日，博瑞转债二级市场价格高达190.519元/张，远超赎回价格100.9452元/张。投资者如未及时转股或卖出，面临重大投资损失。
- 交易与转股截止期限逼近：最后交易日为2026年5月18日，最后转股日为2026年5月21日，赎回登记日后未转股债券将全部冻结并强制赎回。
- 质押或冻结风险：如“博瑞转债”处于质押或冻结状态，建议投资者于停止交易日前解除相关状态，否则可能面临无法转股、被强制赎回的风险。
- 投资者适当性风险：不符合科创板股票投资者适当性要求者，仅能被赎回，无法转为股票，可能导致亏损。
操作建议
- 持有人应立即根据自身情况，选择在规定期限内转股或通过二级市场卖出，以避免损失。
- 已办理指定交易的投资者可在赎回款发放日领取赎回款。
- 未办理指定交易的投资者需先办理指定交易后方可领取赎回款。
联系方式
如有疑问，投资者可联系公司证券部（电话：0512-62620988，邮箱：[email protected]）。
三、对公司及股价的潜在影响（价格敏感信息）
- 本次提前赎回表明公司股票表现强劲，已满足较高的赎回触发条件，反映了市场对公司前景的高度认可。
- 可转债提前赎回后，流通在外的债券转为股票的压力可能减轻，对公司股价存在积极影响。
- 若部分投资者因未及时操作而遭受损失，可能短期内对市场情绪产生负面影响。
免责声明
本文基于公司公开披露信息整理，仅供参考，不构成任何投资建议。投资者应结合自身情况、风险承受能力和市场变化审慎决策，必要时请咨询专业顾问。公司及作者不对因使用本文内容导致的任何损失承担责任。
English Translation
In-depth Analysis of BrightGene Bio-Medical Technology (Suzhou) Co., Ltd. Convertible Bond (“BrightGene Convertible”) Redemption and Delisting Announcement
Key Points of the Announcement
- Redemption Record Date: May 21, 2026
- Redemption Price: 100.9452 RMB per bond (pre-tax, includes accrued interest); individual investors receive 100.7562 RMB per bond after tax
- Redemption Payment Date: May 22, 2026
- Last Trading Day: May 18, 2026
- Last Conversion Day: May 21, 2026
- Delisting Date: May 22, 2026
- Reason for Redemption: The company’s stock price closed at or above 130% of the conversion price for at least 15 out of 30 consecutive trading days, triggering the forced redemption clause
Details and Investor Instructions
On April 27, 2026, the board of BrightGene resolved to exercise its right to early redeem the convertible bond, as the stock price met the redemption trigger condition. Accrued interest is calculated at 0.9452 RMB per bond; the redemption price totals 100.9452 RMB per bond.
- Individual investors are subject to a 20% withholding tax on the interest portion; after-tax redemption amount is 100.7562 RMB per bond.
- Resident enterprises pay their own corporate income tax, receiving 100.9452 RMB per bond pre-tax.
- Qualified Foreign Institutional Investors (QFII, RQFII) are exempt from corporate income tax and VAT, also receiving 100.9452 RMB per bond.
Investor Risks and Reminders
- Significant Price Gap: As of May 13, 2026, the market price of the convertible bond was 190.519 RMB, much higher than the redemption price. Failure to convert or sell in time may lead to substantial losses.
- Imminent Deadlines: Last trading date is May 18, 2026; last conversion date is May 21, 2026; after the record date, non-converted bonds will be frozen and forcibly redeemed.
- Pledge/Freeze Risk: If the bond is pledged/frozen, investors must release it before the trading halt to avoid forced redemption without conversion.
- Eligibility Risk: Investors not meeting the STAR Market stock investor suitability criteria can only be redeemed (not converted), risking losses if the redemption price is lower than their cost.
Action Recommendations
- Bondholders should immediately decide whether to convert or sell in the secondary market before the deadlines to avoid losses.
- Designated trading investors can collect redemption payments on the payment date; non-designated investors must complete designation first.
Contact Information
For queries, contact the company’s securities department: 0512-62620988, [email protected].
Potential Impact on Company and Stock Price (Price Sensitive Information)
- The redemption trigger signals strong share price performance and high market expectations for the company’s prospects.
- After redemption, the convertible bond overhang will be removed, which may positively affect the stock price.
- If some investors incur losses due to missing the deadline, short-term negative sentiment may arise.
Disclaimer
This article is compiled based on publicly disclosed information and is for reference only. It does not constitute investment advice. Investors should make prudent decisions based on their own circumstances and consult professional advisors if needed. The company and the author are not responsible for any losses arising from the use of this content.
